Improvement in Myoclonus–Dystonia Syndrome during Treatment with Gonadotropin‐Releasing Hormone Agonist
2023; Wiley; Volume: 10; Issue: 12 Linguagem: Inglês
10.1002/mdc3.13883
ISSN2330-1619
AutoresJoão Moura, Marina Gallottini,
Tópico(s)Autoimmune Neurological Disorders and Treatments
ResumoMovement Disorders Clinical PracticeVolume 10, Issue 12 p. 1812-1814 CASE REPORT Improvement in Myoclonus–Dystonia Syndrome during Treatment with Gonadotropin-Releasing Hormone Agonist João Moura MD, Corresponding Author João Moura MD [email protected] orcid.org/0000-0002-4212-906X Neurology Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal Correspondence to: Dr. João Moura, Neurology Department, Centro Hospitalar Universitário de Santo António, Largo do Professor Abel Salazar, 4099-001 Porto, Portugal; E-mail: [email protected]Search for more papers by this authorMarina Magalhães MD, Marina Magalhães MD Neurology Department, Centro Hospitalar Universitário de Santo António, Porto, PortugalSearch for more papers by this author João Moura MD, Corresponding Author João Moura MD [email protected] orcid.org/0000-0002-4212-906X Neurology Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal Correspondence to: Dr. João Moura, Neurology Department, Centro Hospitalar Universitário de Santo António, Largo do Professor Abel Salazar, 4099-001 Porto, Portugal; E-mail: [email protected]Search for more papers by this authorMarina Magalhães MD, Marina Magalhães MD Neurology Department, Centro Hospitalar Universitário de Santo António, Porto, PortugalSearch for more papers by this author First published: 15 September 2023 https://doi.org/10.1002/mdc3.13883Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Roze E, Lang AE, Vidailhet M. Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. Curr Opin Neurol 2018; 31: 484–490. 10.1097/WCO.0000000000000577 PubMedWeb of Science®Google Scholar 2Menozzi E, Balint B, Latorre A, Valente EM, Rothwell JC, Bhatia KP. Twenty years on: myoclonus-dystonia and ε-sarcoglycan— neurodevelopment, channel, and signaling dysfunction. Mov Disord 2019; 34: 1588–1601. 10.1002/mds.27822 CASPubMedWeb of Science®Google Scholar 3Fearon C, Peall KJ, Vidailhet M, Fasano A. Medical management of myoclonus-dystonia and implications for underlying pathophysiology. Park Relat Disord 2020; 77: 48–56. 10.1016/j.parkreldis.2020.06.016 PubMedWeb of Science®Google Scholar 4Hainque E, Vidailhet M, Cozic N, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology 2016; 86: 1729–1735. 10.1212/WNL.0000000000002631 CASPubMedWeb of Science®Google Scholar 5Luciano AY, Jinnah HA, Pfeiffer RF, Truong DD, Nance MA, LeDoux MS. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Park Relat Disord 2014; 20: 1423–1426. 10.1016/j.parkreldis.2014.09.029 PubMedWeb of Science®Google Scholar 6Lee JH, Lyoo CH, Lee MS. A patient with genetically confirmed myoclonus-dystonia responded to anticholinergic treatment and improved spontaneously. J Clin Neurol 2011; 7: 231–232. 10.3988/jcn.2011.7.4.231 PubMedWeb of Science®Google Scholar 7Chang V, Mingbunjerdsuk D. Dystonia responding to Levodopa in a child with myoclonus-dystonia. Mov Disord Clin Pract 2023; 10: 687–690. 10.1002/mdc3.13708 CASPubMedWeb of Science®Google Scholar 8Belli E, Del Prete E, Unti E, Mazzucchi S, Palermo G, Ceravolo R. Perampanel as a novel treatment for subcortical myoclonus in myoclonus-dystonia syndrome. Neurol Sci 2023; 44: 1–3. 10.1007/s10072-023-06803-y Web of Science®Google Scholar 9Gazzina S, Alberici A, Padovani A, Borroni B. Myoclonic dystonia (DYT11) responsive to insulin therapy: a case report. Neurology 2017; 89: 517–518. 10.1212/WNL.0000000000004182 PubMedWeb of Science®Google Scholar 10Kompoliti K, Goetz CG, Vu TQ, Carvey PM, Leurgans S, Raman R. Estrogen supplementation in the posthypoxic myoclonus rat model. Clin Neuropharmacol 2001; 24: 58–61. 10.1097/00002826-200101000-00010 CASPubMedWeb of Science®Google Scholar 11Tai KK, Bhidayasiri R, Truong DD. Post-hypoxic animal model of myoclonus. Park Relat Disord 2007; 13: 377–381. 10.1016/j.parkreldis.2007.07.001 PubMedWeb of Science®Google Scholar 12Jo S, Park KW, Choi N, Ryu HS, Kim KJ, Kim YJ, Chung SJ. Paroxysmal generalized dystonia with clinical fluctuation affected by the menstrual cycle. Park Relat Disord 2020; 75: 48–49. 10.1016/j.parkreldis.2020.05.009 PubMedWeb of Science®Google Scholar 13Gwinn-Hardy KA, Adler CH, Weaver AL, Fish NM, Newman SJ. Effect of hormone variations and other factors on symptom severity in women with dystonia. Mayo Clin Proc 2000; 75: 235–240. 10.1016/S0025-6196(11)65026-X CASPubMedWeb of Science®Google Scholar 14Lim ECH, Seet RCS, Wilder-Smith E, Ong BKC. Dystonia gravidarum: a new entity? Mov Disord 2006; 21: 69–70. 10.1002/mds.20648 PubMedWeb of Science®Google Scholar 15Raymond D, Saunders-Pullman R, de Carvalho AP, et al. Phenotypic spectrum and sex effects in eleven myoclonus-dystonia families with ε-sarcoglycan mutations. Mov Disord 2008; 23: 588–592. 10.1002/mds.21785 CASPubMedWeb of Science®Google Scholar Volume10, Issue12December 2023Pages 1812-1814 ReferencesRelatedInformation
Referência(s)